Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Most Patients with Breast and Ovarian Cancer Do Not Undergo Genetic Testing

Most Patients with Breast and Ovarian Cancer Do Not Undergo Genetic Testing

Cancers arise for 3 main reasons: hereditary, familial, and sporadic

  • Hereditary cancers account for about 10-15% of all cancers. This proportion was previously thought to be around 5%, but advances in genetics have better characterized the genetic changes underlying cancers, and hereditary cancer genes were found to play a greater role than previously believed (see HEREDITARY Mutations Cause 1 in Every 8 Cancers). The first cancers that come to mind when hereditary cancer is mentioned are breast, ovarian, colorectal, uterine, pancreatic, stomach, and prostate cancer. If a patient develops one of these cancers, especially before the age of 50, heredity should be considered, and, for the patient and their family, genetic testing should be recommended. 
  • Familial cancers are estimated to account for about 10% of all cancers. In familial cancers, no cancer gene alteration passed down from the mother or father can be identified, but certain cancers tend to occur more frequently in that family than in the general population.
  • Sporadic cancers account for about 75-80% of all cancers. These cancers arise from genetic changes caused by environmental factors over a lifetime. The main causes of sporadic cancers, in order of importance, are aging, smoking, obesity, various viral and bacterial infections, alcohol, ultraviolet rays from the sun, and chemical carcinogens. 

25-30% of Ovarian Cancers and 10-15% of Breast Cancers Are Hereditary

The number of genes tested for hereditary ovarian and breast cancer has increased in recent years, but most patients do not undergo genetic testing. Consequently, according to a study in Journal of Clinical Oncology, published results show that genetic changes of unknown clinical significance — known in genetics as VUS (variant of uncertain significance) — are common, especially among minority populations.

What Is VUS?

Variant of Uncertain Significance (VUS): Sometimes a genetic test finds a change in hereditary cancer genes (for example BRCA1 and BRCA2) that has not previously been associated with cancer and is rare in the general population. This type of test result is called a "variant of uncertain significance" or VUS because it is not clearly known whether this specific genetic change is harmful. However, as genetic data accumulate, a genetic change identified as a VUS today may be classified as a harmful mutation in the future.

Details of the Study

  • The study evaluated genetic testing trends and results in 187,535 patients with breast cancer and 14,689 patients with ovarian cancer, all diagnosed between 2013-2017.
  • The results found that only 34% of patients with ovarian cancer and 25% of patients with breast cancer underwent genetic testing for hereditary susceptibility.
  • Although the number of genes tested increased by 28% each year and VUS detection rates also rose markedly, the number of patients undergoing testing increased by only 2% each year.
  • Among patients with breast cancer, 8.5% of those diagnosed in early 2013 had a VUS, while the VUS detection rate reached 22% by the end of 2017.

The rates of VUS results were found to be significantly higher for members of racial minority groups with breast or ovarian cancer than for white patients. Multivariable analysis identified race or ethnicity only as a significant predictor of VUS results. Higher VUS rates in different ethnic groups may be explained by less genetic testing having previously been performed in these populations. As genetic testing becomes more frequent in these populations, it will become clearer whether VUS are harmful genetic changes.

Most harmful mutations for breast and ovarian cancer have been identified in 20 genes. The study authors explained that focusing specifically on these 20 genes could maximize clinically relevant pathogenic variant results while minimizing VUS results, especially in patients from racial or ethnic minority groups.

Hereditary cancer genes and their associated cancers can be seen below:
what are hereditary cancer genes and mutations

According to the study authors, better characterization of hereditary cancers requires focusing on more in-depth analysis of existing genes rather than examining more genes per test.

*

RELATED TOPICS

Who Should Undergo Genetic Testing for Hereditary Breast Cancer?

Is Ovarian Cancer Hereditary? What Are the Genetic Risk Factors?

Psychological Effects of Hereditary Cancer Screening (Genetic Tests)

Sources

Kurian AW, Ward KC, Abrahamse P, et al. Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019. J Clin Oncol. Published online February 9, 2021.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Most Patients with Breast and Ovarian Cancer Do Not Undergo Genetic Testing

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy